While our 3-month data showed no significant renal impairment or electrolyte imbalances, the long-term effects and optimal monitoring strategies for renal function and electrolytes in post-AMI HF patients receiving SGLT2 inhibitors remain important considerations for future studies with extended follow-up. This evidence concerns the gene SLC5A2 and hydrops fetalis.